Vanni Gianluca, Selntigia Aikaterini, Marsella Valentina Enrica, Russo Consuelo, Pellicciaro Marco, Materazzo Marco, Rizzo Giuseppe, Buonomo Oreste Claudio, Exacoustos Caterina
Breast Unit, Department of Surgical Science, University of Rome "Tor Vergata", Viale Oxford 81, 00133 Rome, Italy.
Obstetrics and Gynecological Unit, Department of Surgical Science, University of Rome "Tor Vergata", Viale Oxford 81, 00133 Rome, Italy.
Medicina (Kaunas). 2024 Apr 12;60(4):625. doi: 10.3390/medicina60040625.
: The association between endometriosis and breast cancer still remains controversial. The aim of this study was to investigate the different subtypes of breast cancer, immunohistochemical markers, hormone receptors, and ki67 proliferation indexes in patients with and without endometriosis and/or adenomyosis. : All patients with endometriosis and breast cancer were enrolled. Women with endometriosis and breast cancer (Group BC+EN+) were compared to patients with breast cancer without endometriosis (group BC+EN-) and those with endometriosis without breast cancer (group BC-EN+). General population characteristics and histological and immunohistochemical subtypes of breast cancer were compared between groups. : Our study included 41 cases affected by both endometriosis and/or adenomyosis and breast cancer (Group BC+EN+) that were matched (1:2) with 82 patients affected only by breast cancer (group BC+EN-) and 82 patients affected only by endometriosis and/or adenomyosis (group BC-EN+). Group BC+EN+ presented a higher percentage of ER receptor expression (83% vs. 70%, = 0.02), as well as lower values of Ki 67% (15% vs. 24%, < 0.0001) and HER2+ (9.8% vs. 28%, = 0.022). These findings were more evident when comparing patients with premenopausal status, while in postmenopausal patients, this difference was no longer significant. Regarding endometriosis, no statistical differences were observed in type or specific localization of the disease among the groups with and without breast cancer. : Patients with endometriosis presented lower aggressive breast cancer rates with higher values of ER% and lower values of Ki 67 and HER2neu+. The type and severity of endometriotic diseases seemed not to influence breast cancer occurrence.
子宫内膜异位症与乳腺癌之间的关联仍存在争议。本研究的目的是调查患有和未患有子宫内膜异位症和/或子宫腺肌病的患者中乳腺癌的不同亚型、免疫组化标志物、激素受体和Ki67增殖指数。
所有患有子宫内膜异位症和乳腺癌的患者均被纳入研究。将患有子宫内膜异位症和乳腺癌的女性（BC+EN+组）与未患有子宫内膜异位症的乳腺癌患者（BC+EN-组）以及患有子宫内膜异位症但未患有乳腺癌的患者（BC-EN+组）进行比较。比较各组之间乳腺癌的一般人群特征、组织学和免疫组化亚型。
我们的研究纳入了41例同时患有子宫内膜异位症和/或子宫腺肌病以及乳腺癌的患者（BC+EN+组），这些患者与82例仅患有乳腺癌的患者（BC+EN-组）和82例仅患有子宫内膜异位症和/或子宫腺肌病的患者（BC-EN+组）进行匹配（1:2）。BC+EN+组的ER受体表达百分比更高（83%对70%，P = 0.02），同时Ki67%的值更低（15%对24%，P < 0.0001）以及HER2+更低（9.8%对28%，P = 0.022）。当比较绝经前患者时，这些发现更为明显，而在绝经后患者中，这种差异不再显著。关于子宫内膜异位症，在患有和未患有乳腺癌的组之间，疾病的类型或特定定位未观察到统计学差异。
患有子宫内膜异位症的患者侵袭性乳腺癌发生率较低，ER%值较高，Ki67和HER2neu+值较低。子宫内膜异位症疾病的类型和严重程度似乎不影响乳腺癌的发生。
